• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

ESMO Breast Cancer 2024

May 15 - 17, 2024

  1. Trastuzumab deruxtecan
  2. Camizestrant
  3. Capivasertib
  4. Datopotamab deruxecan

pdf

A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor–positive (HR+), HER2-low metastatic breast cancer (mBC)

pdf

Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)

pdf

Exploratory pooled safety analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2+ or HER2-low unresectable and/or metastatic breast cancer (mBC) in DESTINY-Breast trials

pdf

PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)

pdf

Trastuzumab deruxtecan (T-DXd) vs Treatment of Physicians' choice (TPC) in patients with HER2+ metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1): Updated Overall Survival (OS) Results of the randomized, phase 3 DESTINY-Breast02 (DB02)

pdf

Trastuzumab deruxtecan (T-DXd) for Advanced Breast Cancer (ABC) patients (pts), regardless of HER2 status: A phase II study with Biomarkers Analysis (DAISY) Update analysis with longer follow-up

pdf

Dynamics of ESR1m ctDNA in patients with ER+ HER2- metastatic breast cancer receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial.

pdf

Capivasertib and fulvestrant for patients with AI-resistant HR+/HER2– ABC: PFS2 and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial

ppt

TROPION-Breast04: Phase (Ph) 3 study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (durva) followed by adjuvant (adj) durva vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2– breast cancer (BC)

ppt

TROPION-Breast05: Phase (Ph) 3 study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (durva) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

ppt

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2- breast cancer (BC): Additional safety analysis from TROPION-Breast01

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice